Legend Biotech Corporation - American Depositary Shares (LEGN)

Today, August 11, 2025, marks a significant day for investors looking beyond the typical S&P 500 giants, as a diverse array of companies across various sectors unveiled their latest quarterly earnings. These reports, ranging from cybersecurity and fintech to mining and life sciences, offer a crucial granular view into

Legend Biotech's Q2 2025 earnings show revenue beat at $255.1M, driven by strong CARVYKTI sales, but EPS missed at -$0.34. Stock rose 1.4% pre-market.

Nicole Verdun and Rachael Anatol were placed on administration leave without explanation.

Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks.